Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00730171 · ClinicalTrials.gov registry record · Phase 3
An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation
A Phase 3 study, sponsored by Ironwood Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,743
- Enrollment target
NCT00730171 is a Phase 3 study that has completed, run by Ironwood Pharmaceuticals. The registered enrollment target is 1,743 participants.
The verdict
NCT00730171, a Phase 3 study, has completed, sponsored by Ironwood Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,743 participants
- Enrollment target
Study Summary
The objective of this study is to assess the long-term safety of linaclotide administered to patients with chronic constipation (CC) or irritable bowel syndrome with constipation (IBS-C).
Interventions
- DRUG Linaclotide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,743 participants |
| Start Date | 2008-09 |
| Est. Completion | 2012-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00730171
The ClinicalTrials.gov registry entry for NCT00730171 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,743 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ironwood Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Linaclotide is the first listed.
NCT00730171 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00730171 about?
NCT00730171 is a clinical study titled "An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation". The objective of this study is to assess the long-term safety of linaclotide administered to patients with chronic constipation (CC) or irritable bowel syndrome with constipation (IBS-C).
What is the current status of trial NCT00730171?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,743 participants. The study started on 2008-09. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00730171?
The interventions under investigation include: Linaclotide (DRUG).
Who is sponsoring clinical trial NCT00730171?
This trial is sponsored by Ironwood Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.